The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offisite pharmacy and delivered as a ready-to-use unit dose. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a novel PET radiotracer for evaluation of possible MI and ischemia. The approval is based on ...

Chicago, Illinois (Embargoed until 2:15 p.m. CDT, Tuesday, June 27, 2023)—A novel PET perfusion radiotracer, 18 F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a ...

A novel PET perfusion radiotracer, 18 F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99m Tc-SPECT myocardial ...

BARCELONA -- Cardiac magnetic resonance (CMR) and 82 rubidium positron emission tomography (Rb-PET) performed equally well for perfusion imaging after coronary CT angiography, although with only ...

Using serial PET imaging to guide revascularization decisions, alongside a comprehensive strategy of risk-factor control and lifestyle changes, significantly reduces coronary artery disease risk and ...

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...